{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Complete Response/CR"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Very Good Partial Response/PR"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"Partial Response/PR"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Minimal Response/MR"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Stable Disease/SD"},{"measurements":[{"groupId":"OG000","value":"12"}],"title":"Progressin of Disease/POD"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions","groups":[{"description":"A single arm, open-label, single institution phase 2 clinical trial is planned.\n\nCarfilzomib: Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.","id":"OG000","title":"Carfilzomib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who completed 4 cycles of treatment or whose disease progressed prior to completion of 4 cycles.","reportingStatus":"POSTED","timeFrame":"2 years","title":"To Evaluate the Best Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}